The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2023 | Should we delay transplantation in patients with standard-risk multiple myeloma?
Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, comments on changes in the use of stem cell transplantation (SCT) as a frontline therapy for younger, standard-risk, transplant-eligible patients with multiple myeloma. Dr Richardson discusses results from the DETERMINATION Phase III clinical trial (NCT01208662) which has demonstrated that overall survival (OS) outcomes are comparable across groups of patients undergoing early versus late transplant. Dr Richardson further highlights advantages and disadvantages of delaying SCT in certain patient populations, and explains the importance of having access to novel agents. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting: Oncopeptides, Celgene/BMS, Karyopharm, Sanofi, GSK, Janssen, Takeda
Oncopeptides, Celgene/BMS, Karyopharm, Takeda
